Search
Revakinagene taroretcel
go.drugbank.com/drugs/DB05344ApprovedInvestigational(rhCNTF) (NTC-201-6A cell line) for surgical intravitreal placement. … [A265115] On March 6, 2025, FDA approved revakinagene taroretcel for the treatment of idiopathic macular telangiectasia type 2.
Synonyms: An allogeneic human adult retinal pigment epithelial (RPE) cell line stably transfected with a plasmidMenadione
go.drugbank.com/drugs/DB00170ApprovedNutraceuticalA synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted to active vitamin K2, menaquinone, after alkylation in vivo.
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP1A2 InhibitorsSulfoxone
go.drugbank.com/drugs/DB01145ApprovedSulfoxone is a water-soluble sulfone used as an antileprosy drug. It has been used with limited success in the treatment of dermatitis herpetiformis.
Categories: Drugs for Treatment of Lepra, Antiinfectives for Systemic UseGavorestat
go.drugbank.com/drugs/DB16707InvestigationalGavorestat is under investigation in clinical trial NCT04902781 (Clinical Benefit, Safety, PK and PD Study of AT-007 in Pediatric Subjects With Classic Galactosemia).
Relacorilant
go.drugbank.com/drugs/DB14976ApprovedInvestigational[L56089] Relacorilant was approved by the US FDA on March 25, 2026, for use in combination with [paclitaxel] in patients with certain platinum-resistant cancers.[L56093,L56089] … Relacorilant is a first-in-class, selective glucocorticoid receptor antagonist.
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2C8 InducersCalcipotriol
go.drugbank.com/drugs/DB02300ApprovedInvestigationalCalcipotriol (INN) or calcipotriene (USAN) is a sythetic derivative of calcitriol or Vitamin D.
Mixtures: Enstilar 50 Mikrogramm/g + 0,5 mg/g Schaum zur Anwendung auf der HautCategories: Antipsoriatics for Topical UseOlutasidenib
go.drugbank.com/drugs/DB16267ApprovedInvestigational[L44256,L44261] It is indicated for the treatment of relapsed or refractory acute myeloid leukemia (AML) in patients with a susceptible IDH1 mutation as determined by an FDA-approved test. … [A254726,L44256] Other IDH1 inhibitors, such as [ivosidenib], have also been approved for the treatment of relapsed or refractory AML.
Categories: Cytochrome P-450 CYP1A2 Inducers, P-glycoprotein inhibitorsLactitol
go.drugbank.com/drugs/DB12942Approved[A190915,A190918] Pizensy, an oral lactitol powder for solution, was approved by the FDA for use in chronic idiopathic constipation in February 2020.[L11803] … [A190912] Clinically, lactitol has been investigated for use as an osmotic laxative and, along with other non-absorbable disaccharides such as [lactulose], in the treatment of hepatic encephalopathy in
Categories: Drugs for ConstipationEmpagliflozin
go.drugbank.com/drugs/DB09038ApprovedInvestigationalEmpagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. … [A203453] It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 diabetes mellitus.
Categories: P-glycoprotein substratesDesipramine
go.drugbank.com/drugs/DB01151ApprovedThey contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation. … See toxicity section below for a complete listing of side effects.
Categories: Antidepressive Agents Indicated for Depression, Serotonin Receptor Antagonists